Zoetis Inc. (ZTS) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. Despite some positive growth in international revenue and livestock, U.S. revenue declined due to competition and market contraction. The Q&A section highlights management's strategies to address challenges but lacks specific details, leading to uncertainties. While there is optimism in product innovation and market expansion, the competitive pressures and affordability issues remain concerns. Given these factors, the stock price is likely to remain stable, resulting in a neutral sentiment.
Key Financial Performance
Revenue Revenue was flat on an organic operational basis. The International segment delivered 10% organic operational revenue growth, while the U.S. declined 8%. By species, livestock delivered 12% organic operational revenue growth, while companion animal declined 4% operationally. Reasons for changes include increased competition, price sensitivity, and market dynamics.
Adjusted Net Income Adjusted net income grew 1% on an organic operational basis. Reasons for changes include cost and productivity programs and macroeconomic factors.
Global Revenue Global revenue was $2.3 billion, growing 3% on a reported basis and flat on an organic operational basis. Reasons for changes include a 2% growth from price offset by a 2% decline in volume.
Companion Animal Portfolio Revenue Global companion animal portfolio posted $1.5 billion in revenue, declining 4%. Reasons for changes include increased competition, price sensitivity, and lower clinic traffic.
Key Dermatology Revenue Key dermatology recorded $347 million in revenue, down 11%. Reasons for changes include increased competition and price sensitivity.
OA Pain mAbs Revenue OA Pain mAbs, Librela and Solensia, posted a combined $140 million in revenue, declining 8%. Reasons for changes include market dynamics and competition.
Simparica Franchise Revenue Simparica franchise contributed $385 million globally, declining 1%. Reasons for changes include competition and market contraction.
Diagnostics Business Revenue Global companion animal diagnostics business posted $113 million in revenue, growing 10%. Reasons for changes include expansion in reference labs and growth in chemistry and hematology.
Livestock Revenue Livestock revenue was $720 million globally, growing 12%. Reasons for changes include favorable producer economics, disease outbreaks, and increased vaccine adoption.
U.S. Revenue U.S. revenue was $1.1 billion, declining 8%. Reasons for changes include price sensitivity, lower clinic traffic, and competition.
International Revenue International revenue grew 17% on a reported basis and 10% on an organic operational basis, posting $1.1 billion in revenue. Reasons for changes include geographic expansion and market dynamics.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Cytopoint Plus: Advancing development to strengthen dermatology leadership.
Lenivia and Portela: Early phases of launches in European markets and Canada to expand OA Pain franchise.
Convenia RTU: Recent Canadian approval expands access through a ready-to-use, cost-effective formulation.
International segment: Delivered 10% organic operational revenue growth, supported by geographic expansion of portfolio.
Emerging markets: Continued to provide runway for expansion, with meaningful market opportunities remaining.
Cost and productivity program: Launched to tighten discretionary spending, drive procurement and operating efficiencies, and assess organizational levers for a leveraged P&L in 2026 and beyond.
Commercial execution: Sharpening execution across core commercial levers, focusing on integrated solutions for veterinarians and targeted DTC activity for pet owners.
Neogen's animal genomics business acquisition: Expanding capabilities in livestock genetics to unlock new sources of growth.
Pipeline innovation: Includes 12 potential blockbusters and over $7 billion in additional market opportunity, aiming to extend leadership into new categories of care.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Companion Animal Market Dynamics: Pricing in veterinary clinics continues to rise, leading to lower clinic traffic. Pet owners are showing increased price sensitivity, resulting in softer demand for premium products in preventative and chronic care. Competition has intensified in key pet care categories, including dermatology and parasiticides, with aggressive pricing and incentives from competitors. These dynamics have led to delayed routine visits, extended dosing, and reduced clinic visits, compounded by winter storms.
Competitive Pressures: Increased competition in dermatology and parasiticides, with new entrants offering aggressive pricing and incentives, has pressured Zoetis' market share. Generic competition has also impacted key products like Convenia and Cerenia, leading to significant share loss.
Market Contraction: The companion animal market has not expanded despite new entrants, resulting in a more price-sensitive and competitive environment. This has particularly impacted Zoetis' premium product lines.
U.S. Companion Animal Business: The U.S. market has seen significant declines due to price sensitivity, lower clinic traffic, and intensified competition. Distributor and retail channel purchasing patterns have also been a headwind, with promotions underperforming and end-market demand softening.
Regulatory and Label Updates: Ongoing regulatory reviews and label updates for products like Librela have created challenges in building veterinary prescribing confidence, though efforts are being made to address this.
Economic and Consumer Sentiment: Macroeconomic factors and consumer price sensitivity are pressuring pet owner spending, particularly in developed markets. This has led to declines in key product categories and overall market contraction.
Livestock Business: While livestock has shown growth, the business remains exposed to disease outbreaks and supply chain challenges, which could impact continuity of supply and responsiveness in key markets.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Zoetis expects full-year revenue growth of 2% to 5% on an organic operational basis for 2026.
Adjusted Net Income Growth: The company projects adjusted net income growth of 2% to 6% for the full year 2026.
Pipeline and Innovation: Zoetis is advancing a pipeline with 12 potential blockbuster products and over $7 billion in additional market opportunities, with significant contributions expected by the end of 2027 and into 2028.
Companion Animal Market Recovery: The company anticipates a path for market recovery over time, despite current challenges in the companion animal segment, including price sensitivity and competition.
Cost and Productivity Program: Zoetis has launched a comprehensive cost and productivity program to improve financial performance, including tightening discretionary spending, driving procurement efficiencies, and assessing organizational levers.
Livestock Growth: The livestock segment is expected to remain a strong source of growth, supported by favorable producer economics, sustained protein demand, and increased adoption of vaccines.
Geographic Expansion: Emerging markets are expected to provide meaningful market expansion opportunities, particularly in the companion animal segment.
Operational Adjustments: Zoetis is focusing on improving commercial execution, enhancing portfolio optimization, and driving cost discipline to navigate the current environment and improve performance over time.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What can Zoetis do in the near term to address growing competitive pressure and consumer challenges?
A:Kristin Peck mentioned focusing on pipeline innovation, expanding markets, and leveraging their broad portfolio. They aim to sharpen their commercial strategy, provide integrated solutions, focus on affordability through loyalty programs, and optimize access via retail and home delivery. They also highlighted stabilization and growth in products like Librela and gains in paras share.
Q:How does Zoetis plan to achieve its full-year growth guidance despite a challenging Q1?
A:Wetteny Joseph explained that the initial guidance already considered first-half to second-half dynamics. They expect stabilization in key areas like Librela and Simparica, and actions taken to address market uncertainties. Easier comps in the second half and calendar adjustments are also factored into the guidance.
Q:What does Zoetis' guidance imply for quarterly progression in companion animal sales?
A:Wetteny Joseph stated that they are not assuming inventory restocking by distributors or retailers. They expect stabilization in end-market demand and are embedding headwinds from competition and macroeconomic pressures. Retail growth has slowed but remains positive, and they are focusing on commercial execution and easier comps in the second half.
Q:Is the animal health market becoming less durable and attractive for Zoetis?
A:Kristin Peck disagreed with this view, emphasizing the structural demand for veterinary care and the strength of the human-animal bond. She noted that while there are current challenges, they believe the market will stabilize. Zoetis does not expect generics in key categories and believes in the differentiation and innovation of their portfolio.
Q:What is Zoetis' pricing strategy in response to competitive pressures?
A:Kristin Peck stated that Zoetis will not compete primarily through price but will focus on their differentiated portfolio, innovation, and service. They are addressing affordability issues for pet owners at the point of sale through loyalty programs and promotions. Wetteny Joseph added that pricing adjustments are made based on market and product-specific factors.
Q:What are Zoetis' expectations for U.S. companion animal growth in 2026?
A:Wetteny Joseph indicated that they expect stabilization in key franchises and low to mid-single-digit growth for companion animal products. Livestock is expected to drive momentum with mid- to high-single-digit growth.
Q:How is Zoetis addressing affordability issues for pet owners?
A:Kristin Peck mentioned enhancing loyalty programs to provide more immediate affordability options at the point of sale, rather than delayed cashback programs. This approach aims to address economic challenges faced by pet owners.
Q:What is Zoetis' level of interest in large-scale transformational business development?
A:Kristin Peck stated that Zoetis focuses on incremental business development rather than large-scale transformational deals. They prioritize investing in their business and look for opportunities like the Neogen deal, which aligns with their strategy.
Q:Can Zoetis accelerate launch timelines for new products in renal, oncology, and cardiology?
A:Kristin Peck mentioned that they are leveraging AI and partnering with the FDA to explore ways to speed innovation and launch timelines. However, products expected in the next few years are already in clinical trials.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the exact impact of channel normalization on U.S. Pet Health in Q1 2026, as well as the precise growth figures for key derm products outside the U.S. They also did not provide clarity on the exact pricing strategy for upcoming innovations in renal, oncology, and cardiology, or the specific impact of competitive pressures on these areas.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Animal health
Canada OA
Convenia RTU
DTC activity
Demand softness
Directorate UK
OA Pain
access
action
basis income
benefit
blockbuster
capability
care spending
companion animal
end market
entrant market
environment term
lever
livestock
market demand
market expansion
momentum
option
owner price
pace
period
premium product
prescription
pressure share
price sensitivity
pricing
priority
productivity
role
source
track
trajectory
use
visit
wave
ZTS Transcript
Zoetis Inc. (ZTS) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call presents a mixed picture. Despite some positive growth in international revenue and livestock, U.S. revenue declined due to competition and market contraction. The Q&A section highlights management's strategies to address challenges but lacks specific details, leading to uncertainties. While there is optimism in product innovation and market expansion, the competitive pressures and affordability issues remain concerns. Given these factors, the stock price is likely to remain stable, resulting in a neutral sentiment.
Zoetis Inc. (ZTS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
Zoetis Inc. (ZTS) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-9
Zoetis Inc. (ZTS) Q4 2025 Earnings Call Transcript
Positive2-12
The earnings call summary and Q&A reveal strong financial performance, especially in companion animal diagnostics and livestock portfolios. Despite competitive pressures, the company maintains a positive outlook with innovative product launches and strategic market positioning. The guidance is optimistic, with expected growth in key segments. Although management was vague on some details, the overall sentiment is positive, supported by strong revenue growth and strategic initiatives.
ZTS Slides
ZTS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
